Myovant Sciences aspires to redefine care for women and men through purpose-driven science, empowering medicines and transformative advocacy.
Our clinical program focuses on developing differentiated solutions that may address high unmet need areas within women’s health and hormone-sensitive oncology. We continuously explore current molecules to potentially expand indications and seek new scientific innovations to enter additional therapeutic areas.
Our current portfolio consists of two molecules, relugolix and MVT-602:
- Relugolix is a gonadotropin-releasing hormone (GnRH) receptor antagonist that reduces sex hormones such as testosterone, estradiol, and progesterone. Relugolix is available as a 120 mg tablet and as a combination tablet (relugolix 40 mg, estradiol 1 mg and norethindrone acetate 0.5 mg). Relugolix is marketed in multiple indications internationally and is currently under investigation for certain uses.
- MVT-602 is an oligopeptide kisspeptin-1 receptor agonist. At present, we’re investigating the potential for multiple indications and therapeutic areas, including as a trigger for of egg maturation in women undergoing assisted reproduction, including in vitro fertilization (IVF), and other potential therapeutic areas.
Learn more about our clinical trials
3 Apr 2023
Sumitomo Pharma Subsidiary Companies in the U.S., Including Sumitovant and its Wholly Owned Subsidiaries, to Combine and Form Sumitomo Pharma America
26 Jan 2023
Myovant Sciences Announces Corporate Updates and Financial Results for Third Fiscal Quarter 2022
You are leaving www.myovant.com, a website provided by Myovant Sciences GmbH.
This link will take you to a different site.